Shao, Spencer
Central Texas Veterans Health Care System
3 papers on CoChatORCID 0000-0002-8390-3824
Most cited papers
- Verified
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 259
- Verified
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Skerget, S., Penaherrera, D., Chari, A., Jagannath, S., Siegel, D. S., Vij, R., Orloff, G., Jakubowiak, A., Niesvizky, R., Liles, D., et al. (2024) · Nature Genetics
Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment
Cited by 95
- Verified
Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8
Lenz, H.-J., Parikh, A. R., Spigel, D. R., Cohn, A. L., Yoshino, T., Kochenderfer, M. D., Elez, E., Shao, S. H., Deming, D. A., Holdridge, R. C., et al. (2022) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers
Cited by 61
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free